Systemic treatment for metastatic or recurrent disease

Gastroesophageal (GE) adenocarcinoma is among the most solid tumor common malignancies worldwide. Despite the declining incidence, prognosis remains dismal, where the malignancy is refractory to conventional cytotoxic chemotherapy and associated with poor prognosis. While therapeutic advances over the past several years have resulted in improved patient outcomes, the observed benefits have been modest, highlighting the need for the identification and usage of novel predictive and diagnostic therapeutic targets. Advances in our understanding of the genomic alterations in key signaling pathways, genetic and epigenetic, hold promise for better treatment outcomes and improvement in patient outcomes in the near future.